Inhibiting enzymes like EZH2 can reactivate tumor suppressor genes, as demonstrated by tazemetostat, while BET protein inhibitors such as JQ1 and CPI-0610 modulate immune checkpoint molecules, reducing tumor-induced immunosuppression. This evidence concerns the gene EZH2 and neoplasm.